The Consultant Who Played Both Sides of China's Hottest Biotech Deal Machine
A lawsuit in New York alleges a former Hengrui dealmaker secretly advised two competing Chinese biotechs at the same time, exposing governance cracks in the booming NewCo licensing model that's reshaping global drug deals. When $110 billion in cross-border deals depends on intermediary trust, one case of alleged double-dealing could change the rules.
A $500,000 Retainer and a Very Awkward Secret
Imagine hiring a real estate agent to sell your house, only to discover they're also working for your neighbor down the street, showing buyers the same comps, whispering the same secrets. Now scale that up to billion-dollar drug deals.
That's roughly the allegation at the center of a new lawsuit filed in New York against Su Zhang, a former global business development head at Hengrui Pharmaceuticals, and her consulting firm CoDevCo. The plaintiff, Lepu Medical Technology, claims Zhang's firm was hired as its exclusive dealmaker to find Western partners for obesity and metabolic-disease assets. The problem? Lepu alleges Zhang was simultaneously serving as chief business officer for BrightGene Pharmaceutical, a direct competitor, without telling Lepu about it.
Lepu is asking for the return of a $500,000 retainer, plus damages and disgorgement of any benefits Zhang's firm collected along the way. The complaint also alleges trade-secret misuse and breach of fiduciary duty.
This isn't just a he-said-she-said dispute between two companies. It's a stress test for the fastest-growing deal structure in global biotech.
The Deal Model That Changed Everything
To understand why this lawsuit matters, you need to understand the NewCo licensing model, which has quietly become one of the most important deal structures in the pharmaceutical world.
The concept is simple in theory. A Chinese biotech takes one of its drug programs, carves out the rights for territories outside China, and drops those rights into a brand-new offshore company (often incorporated in Delaware or the Cayman Islands). Foreign investors buy equity in this NewCo. The Chinese company keeps a stake, giving it long-term upside instead of just a one-time licensing fee.
Think of it like a franchise model for drugs. Instead of selling the recipe outright, you keep ownership of the restaurant chain while someone else opens the international locations.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Before 2024, most Chinese biotech cross-border deals were straightforward licenses: a Western pharma pays upfront fees, milestones, and royalties for the right to develop a drug outside China. The NewCo model flipped the economics. Chinese biotechs could now participate in the upside as shareholders, not just collect checks.
The numbers tell the story. In 2024, Chinese companies struck about 94 cross-border licensing deals worth roughly $51.9 billion. By 2025, that jumped to around 157 deals totaling $137.7 billion, according to data cited by Reuters. And by the first half of 2026, companies had already closed 81 deals worth about $110 billion.
Hengrui itself has been one of the biggest players. The company completed 13 overseas business development transactions since 2023, including a mammoth collaboration with GSK reportedly worth up to $12.5 billion and a deal with Bristol Myers Squibb covering 13 early-stage programs valued at up to $15.2 billion.
The Middlemen Who Make It All Work
But none of these deals happen without intermediaries. Cross-border biotech licensing is absurdly complex: it involves matching Chinese asset owners with foreign capital, navigating IP diligence across jurisdictions, structuring equity splits, and coordinating regulatory approvals in multiple countries.
Consultants and advisors sit at the center of this web. They identify which Chinese drug programs are ready for global development, design the offshore vehicle, negotiate the economics, and often stick around after closing to manage the new entity. In a market moving this fast, trust between parties is the currency that keeps deals flowing.
Which is exactly why the Zhang lawsuit feels like a crack in the foundation.
According to the complaint, CoDevCo was brought on by Lepu in December 2024 as its "exclusive business development mechanism." Zhang had built her reputation at Hengrui, where she helped architect a landmark GLP-1 deal (the hot drug class behind weight-loss blockbusters) that created a NewCo called Hercules backed by private equity and venture capital firms. That pedigree made her a coveted advisor.
Lepu also out-licensed an asset called MWN105 to a NewCo named Sidera Bio in fall 2025, part of the same cross-border boom. But somewhere along the way, Lepu alleges, Zhang started wearing two hats. The complaint claims she took on the CBO role at BrightGene without adequate disclosure, effectively advising two competitors hunting for the same Western partners in the same therapeutic space.
Why This Could Chill the Hottest Market in Biotech
The lawsuit doesn't just raise questions about one consultant. It exposes structural governance risks baked into the NewCo model itself.
Consider how these deals actually get done. The intermediary often has deep visibility into a client's proprietary data: which assets are most advanced, what the internal valuations look like, which partners have expressed interest, and what terms the company would accept. That's sensitive information. If the same advisor is sharing airspace with a direct competitor, the potential for leakage (intentional or not) is enormous.
Legal experts have flagged several pressure points in NewCo governance. Related-party transactions can create self-dealing opportunities. Board composition and voting rights are sometimes structured in ways that sideline minority investors. And vague "commercially reasonable efforts" language in contracts can let the party controlling development shift value away from other stakeholders.
The intermediary problem adds another layer. When consultants shape deal structure, valuation, milestone triggers, and exit mechanics, poorly drafted mandates can let an advisor tilt outcomes toward a preferred investor or repeat client. In a market where average deal sizes reportedly hit $1.3 billion in 2026, even small conflicts can have massive financial consequences.
Will It Actually Slow the Boom?
Probably not. The forces driving China-to-global licensing are just too powerful.
Global pharma companies are staring down patent cliffs and need innovative molecules to fill their pipelines. Chinese biotechs have the assets. Analysts at Nomura were still describing a "high tide" for China-U.S. out-licensing as of September 2026, and Reuters reported that U.S. Treasury rules under discussion would likely preserve most pharma licensing activity with China.
But the lawsuit will almost certainly make buyers more cautious about who's brokering their deals. Expect tighter conflict-of-interest clauses in consulting agreements, more rigorous disclosure requirements, and harder questions during diligence about who else an advisor is representing.
The NewCo model isn't going anywhere. It's too valuable for both sides. Chinese biotechs get long-term equity upside; Western investors get access to innovative drugs without building R&D operations in China from scratch. The economics are simply too compelling.
What may change is the scrutiny around the people in the middle. In a market built on trust, one very public lawsuit can do more to reshape behavior than any regulation. The intermediaries who've been operating in gray zones just got a very loud wake-up call.
For an industry that crossed $110 billion in cross-border deals in a single half-year, that's probably healthy. The pipes are fine. They just need better plumbing inspectors.
6 min read
The $3.9 Million Shot That Could Save Kids With No Other Options
For decades, families with Sanfilippo syndrome were told to take their kids home and love them. Now a $3.9 million gene therapy from Ultragenyx is the first FDA-approved treatment for this fatal childhood brain disease, and it's part of a wave that's reshaping rare disease medicine.
